Table 1 |
|||
|
Genetic Abnormalities in Normal Cytogenetic AML |
|||
| Name |
Prognosis |
Prevalence |
Expression |
|
|
|||
| NPM-1 |
Favorable |
50–60% |
Mutation |
|
|
|||
| FLT3-ITD |
Unfavorable |
30–40% |
Mutation |
|
|
|||
| FLT3-Asp835 |
Unclear |
5–10% |
Mutation |
|
|
|||
| BAALC |
Unfavorable |
65.7% |
Over expression |
|
|
|||
| MN1 |
Unfavorable |
50% |
Over expression |
|
|
|||
| MLL-PTD |
Unfavorable |
7.7% |
Mutation/over expression |
|
|
|||
| CEBPα |
Favorable |
15–20% |
Mutation |
|
|
|||
| ERG-1 |
Unfavorable |
25% |
Over expression |
|
|
|||
| AF1q |
Unfavorable |
75% |
Over expression |
Gregory et al. Journal of Hematology & Oncology 2009 2:23 doi:10.1186/1756-8722-2-23 |
|||
